

Now with NUVESSA® BV dosing can be...


Scan to visit the HCP website

One & Done[a]

Is **medication adherence** a challenge for your patients with bacterial vaginosis (BV)?

- **Patient adherence rates to a multi-day metronidazole regimen are as low as 50%[1]**
- **Over half of women contracting BV may have recurrence within one year[2,3]**
- **Duration of therapy is a potential barrier to adherence for BV treatments[4]**

Percentage of women experiencing repeat BV episodes within 1 year[2,3,b]



a In a clinical study, Nuvessa® demonstrated significantly higher cure rates over a vehicle gel.
b Recurrence defined as Nugent score 7–10 after treatment with oral metronidazole 400 mg twice daily for 7 days. Study follow-up included 1, 3, 6, and 12 months.[3]

Single-dose intravaginal treatments may provide an option for patients who desire **greater convenience** than multidose regimens.[4]

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

NUVESSA® (metronidazole vaginal gel 1.3%) is an intravaginal treatment indicated for the treatment of bacterial vaginosis in females 12 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

NUVESSA is contraindicated in:

- Patients with a history of hypersensitivity to metronidazole, parabens, other ingredients of the formulation, or other nitroimidazole derivatives.
- Patients using disulfiram or within 2 weeks of disulfiram use.

Please see Important Safety Information continued on adjacent page and accompanying full Prescribing Information.



Now with NUVESSA® BV dosing can be...

Scan to visit the HCP website

One & Done[a]

Help your patient adhere to BV treatment[1] with NUVESSA® — the one and only single-dose metronidazole vaginal gel (MVG) for bacterial vaginosis BV

- ✔ In a clinical study, a single dose of 1.3% MVG demonstrated comparable efficacy to a 5-dose regimen of 0.75% MVG[4]
- ✔ 1 pre-filled applicator offers ease of use at bedtime[5]
- ✔ 1 targeted dose at the site of infection minimizes unnecessary drug exposure[6]

NUVESSA® Patient Savings Program

Visit: NUVESSA.COM

Text "NUVESSA" to 31700

for your patients who prefer to get the copay card on their mobile device.

Eligible patients may pay as little as $25[c] for their prescription

a In a clinical study, Nuvessa® demonstrated significantly higher cure rates over a vehicle gel.
c The patient is responsible for the first $25 of their co-pay and cash-paying patients should pay approximately $55. For cash paying patients or insured patients when NUVESSA® is not covered by primary insurance, patients may still use this savings card but may have an outstanding balance. Please see Program Terms, Conditions, and Eligibility Criteria on back of savings card.

To ensure your patients receive NUVESSA®, add "Dispense as written"

Make sure your patients get the only single-dose, single-use metronidazole vaginal gel 1.3% treatment for BV



References: 1. Bartley JB, et al. *Sex Transm Dis.* 2004;31(8):488-491. **2.** Sherrard J, et al. 2023 update to 2018 European (IUSTI/WHO) guideline on the management of vaginal discharge. *Int J STD AIDS.* 2023;34(10):745. **3.** Bradshaw CS, et al. *J Infect Dis.* 2006;193(11):1478 -1486. **4.** Chavoustie SE, et al. *J Low Genit Tract Dis.* 2015;19(2):129-134. **5.** FDA. Nuvessa Prescribing Information. **6.** Hirai J, et al. *J Infect Chemother.* 2025;31(11):102826

INDICATION AND IMPORTANT SAFETY INFORMATION (cont'd)

- Patients using alcohol. Alcoholic preparations (e.g., ethanol, propylene glycol) and beverages should not be consumed during and for at least 24 hours after NUVESSA therapy.

WARNINGS and PRECAUTIONS

Central and Peripheral Nervous System Effects

Convulsive seizures, encephalopathy, aseptic meningitis, optic and peripheral neuropathy have been reported in patients treated with oral or intravenous metronidazole. NUVESSA should be administered with caution to patients with central nervous system diseases. Discontinue promptly if abnormal neurologic signs development.

Carcinogenicity in Animals

Metronidazole has been shown to be carcinogenic at high doses administered orally in mice and rats. Unnecessary use of metronidazole should be avoided.

Drug/Laboratory Test Interactions

Metronidazole may interfere with certain serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and glucose hexokinase. Values of zero may be observed.

Adverse Reactions

The most common adverse reactions (≥1%) observed in adult clinical studies were vulvovaginal candidiasis, headache, vulvovaginal pruritus, nausea, diarrhea, and dysmenorrhea.

The most common adverse reactions (≥1%) observed in pediatric clinical studies was vulvovaginal discomfort.

This is not a complete list of risks.

Please see attached full Prescribing Information for detailed information and online at Nuvessa.com.

Please see Important Safety Information continued on adjacent page and accompanying full Prescribing Information.

Alembic Therapeutics

NUVESSA® is a trademark of Alembic Therapeutics, LLC.
© 2026 Alembic Therapeutics. All Rights Reserved
US-NUV-00003 v1.0



NUVESSA®
(metronidazole vaginal gel 1.3%)